SCHEMBL2460970

SCHEMBL2460970

CCCOc1ccc(F)c2c(=O)c(-c3ccc(OC)cc3)cn(COC(=O)c3ccc(OP)cc3)c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.38
CLK1 P49759 1/20 0.35
RAB9A P51151 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
GAA P10253 1/20 0.35
NLRP3 Q96P20 1/20 0.34
PDE4D Q08499 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.33
ALDH1A1 P00352 3/20 0.33
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33
PKM P14618 1/20 0.33
MAPT P10636 5/20 0.32
KMT2A Q03164 2/20 0.32
MAOB P27338 1/20 0.32
GFER P55789 1/20 0.32
GRM7 Q14831 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
THRB P10828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2461073 0.92 SMN1; SMN2 (0.39) CHRM1CLK1RAB9ACNR1CNR2
SCHEMBL15472261 0.92 CHRM1 (0.41) CHRM1CLK1RAB9ACNR1CNR2
SCHEMBL2460971 0.90 CHRM1 (0.36) CHRM1CLK1RAB9ACNR1CNR2
SCHEMBL2549541 0.89 CHRM1 (0.36) CHRM1CLK1RAB9ACNR1CNR2
SCHEMBL2549544 0.89 CHRM1 (0.36) CHRM1CLK1RAB9ACNR1CNR2
SCHEMBL2548972 0.89 CHRM1 (0.36) CHRM1CLK1RAB9ACNR1CNR2
SCHEMBL2463965 0.88 CHRM1 (0.39) CHRM1RAB9AGAAMAOBSMN1; SMN2
SCHEMBL2466832 0.86 CHRM1 (0.39) CHRM1CLK1RAB9ACNR1CNR2
SCHEMBL7910627 0.86 CHRM1 (0.34) CHRM1CLK1RAB9ACNR1CNR2
SCHEMBL2462784 0.86 CHRM1 (0.34) CHRM1CLK1RAB9ACNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364298-B1 QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMA CO LTD (JP) 2016-08-03 EP disclosed
US-9018229-B2 Quinolone compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-04-28 US disclosed
US-RE45108-E1 Quinolone compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-09-02 US disclosed
US-20140045793-A1 QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-02-13 US disclosed
US-8592593-B2 Quinolone compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-11-26 US disclosed
US-20130005675-A1 QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-03 US disclosed
US-8304546-B2 Quinolone compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-11-06 US disclosed
US-20110269705-A1 QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-11-03 US disclosed
EP-2364298-A1 Quinolone compound and pharmaceutical composition Otsuka Pharmaceutical Co., Ltd. (JP) 2011-09-14 EP disclosed
WO-2010064735-A1 QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005675-A1 QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION PARK7, SNCA, LRRK2 CHRM1 170/4885CLK1 2968/4885RAB9A 320/4885
US-20110269705-A1 QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION PARK7, SNCA, LRRK2 CHRM1 170/4885CLK1 2968/4885RAB9A 320/4885
US-20140045793-A1 QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION PARK7, SNCA, LRRK2 CHRM1 170/4885CLK1 2968/4885RAB9A 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.